TY - JOUR
T1 - Why we need continuous pharmaceutical manufacturing and how to make it happen
T2 - a summary of thoughts from the international symposium on continuous manufacturing
AU - Badman, Clive
AU - Cooney, Charles L.
AU - Haslam, Robert T.
AU - Florence, Alastair
AU - Konstantinov, Konstantin
AU - Krumme, Markus
AU - Mascia, Salvatore
AU - Nasr, Moheb
AU - Trout, Bernhardt L.
AU - Baddour, Raymond F.
N1 - 08/02/2020: This article has been made open by the publisher as part of their Covid-19-related resources.
PY - 2019/11/30
Y1 - 2019/11/30
N2 - We make the case for why continuous pharmaceutical manufacturing is essential, what the barriers are, and how to overcome them. To overcome them, government action is needed in terms of tax incentives or regulatory incentives that affect time.
AB - We make the case for why continuous pharmaceutical manufacturing is essential, what the barriers are, and how to overcome them. To overcome them, government action is needed in terms of tax incentives or regulatory incentives that affect time.
KW - continuous manufacturing
KW - pharmaceutical manufacturing
KW - pharmaceutical technology
UR - https://www.sciencedirect.com/journal/journal-of-pharmaceutical-sciences
U2 - 10.1016/j.xphs.2019.07.016
DO - 10.1016/j.xphs.2019.07.016
M3 - Article
SN - 0022-3549
VL - 108
SP - 3521
EP - 3523
JO - Journal of Pharmaceutical Sciences
JF - Journal of Pharmaceutical Sciences
IS - 11
ER -